Septerna's SEP-631 Shows Strong Phase 1 Safety, Advancing to Phase 2 for Mast Cell Diseases
SEPN has more than doubled off its 52-week low of $4.66.
Summary
Septerna announced positive Phase 1 clinical trial data for its oral drug candidate, SEP-631, targeting mast cell-driven diseases. The study showed SEP-631 was well-tolerated, with an adverse event profile comparable to placebo, indicating a strong safety profile. This is a significant de-risking event for the company, as positive safety data is crucial for advancing drug candidates. Septerna plans to initiate Phase 2 development for chronic spontaneous urticaria in 2026, which will be the next key catalyst for the stock.
At the time of this announcement, SEPN was trading at $29.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.66 to $32.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.